focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.50
Bid: 3.00
Ask: 4.00
Change: -0.40 (-10.26%)
Spread: 1.00 (33.333%)
Open: 3.90
High: 0.00
Low: 0.00
Prev. Close: 3.90
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

License Agreement

9 Apr 2010 07:00

RNS Number : 9292J
Proteome Sciences PLC
09 April 2010
 



 

 

Proteome Sciences plc

ProteoPrep License agreement with Sigma-Aldrich

 

 

9th April, 2010 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has entered into a non-exclusive license agreement with Sigma-Aldrich Corporation ("Sigma") under which Sigma will be able to continue selling products under Proteome's registered trademark ProteoPrep® in Europe, Japan and Australia. Sigma is the world's largest supplier of research biochemicals and organic chemicals with over one million customers.

 

There are currently eleven ProteoPrep® kits available from Sigma and the license will also include all future products sold under the ProteoPrep® trademark that contain chemicals and reagents for the disruption of cells, tissues or other biological material and the extraction of biological molecules like proteins, lipids and carbohydrates. It also covers methods and processes relating to assays for the diagnosis of diseases and chemical markers determining targets for drugs and for determining proteins and peptides by disruption of cells, tissues or other biological material. The license provides Proteome with a signature fee and royalties on all ProteoPrep® sales in the jurisdictions listed above.

 

Commenting on the license Christopher Pearce, Chief Executive of Proteome Sciences said:

 

"We are delighted to have concluded the license with Sigma-Aldrich Corporation for the ProteoPrep® trademark and look forward to receiving this new stream of revenue from royalties generated by their successful and expanding range of ProteoPrep® products."

 

 

 

- End -

 

 

For further information please contact:

 

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

 

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLRSDITIII
Date   Source Headline
10th Nov 201710:11 amRNSHolding(s) in Company
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
27th Oct 201711:30 amRNSHolding(s) in Company
27th Oct 201711:30 amRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSHolding(s) in Company
20th Oct 201712:58 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSGCLP Accreditation and Trading Update
3rd Oct 20172:25 pmRNSBlock Admission Return
1st Sep 201712:08 pmRNSIssue of Equity
1st Aug 20177:00 amRNSDirectorate Changes
25th Jul 20177:00 amRNSInterim results for the 6 months to 30 June 2017
11th Jul 201712:00 pmRNSNotice of Results
30th Jun 201710:31 amRNSHolding(s) in Company
30th Jun 20177:00 amRNSStroke Diagnostic- Research Milestone Achieved
12th Jun 20177:00 amRNSNew Registered Address
8th Jun 20174:40 pmRNSSecond Price Monitoring Extn
8th Jun 20174:35 pmRNSPrice Monitoring Extension
15th May 20177:00 amRNSDirector/PDMR Shareholding
10th May 201710:09 amRNSDirector/PDMR Shareholding
5th May 201712:30 pmRNSDirector/PDMR Shareholding
4th May 20172:23 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20174:58 pmRNSDirector/PDMR Shareholding
28th Apr 20174:54 pmRNSHolding(s) in Company
25th Apr 20171:34 pmRNSAGM Statement and Result of AGM
11th Apr 20177:00 amRNSDirector Dealing and Total Voting Rights
4th Apr 20175:00 pmRNSHolding(s) in Company
4th Apr 20174:40 pmRNSSecond Price Monitoring Extn
4th Apr 20174:35 pmRNSPrice Monitoring Extension
4th Apr 20177:00 amRNSOption Awards
3rd Apr 20177:00 amRNSAppointment of Richard Dennis as CCO
31st Mar 20174:45 pmRNSBlock Admission Return
28th Mar 20177:00 amRNSPreliminary Results
9th Feb 20177:00 amRNSTrading Update & Notice of Results
4th Jan 20174:36 pmRNSHoldings in Company / PDMR Shareholding
3rd Jan 20171:34 pmRNSHoldings in Company / PDMR Shareholding
30th Dec 201611:42 amRNSHolding(s) in Company
19th Dec 20167:00 amRNSLaunch of new website
16th Dec 20169:28 amRNSHolding(s) in Company
29th Nov 201610:43 amRNSResult of GM and Completion of Placing
18th Nov 20169:46 amRNSHolding(s) in Company
8th Nov 201610:12 amRNSHolding(s) in Company
4th Nov 20163:52 pmRNSDirector/PDMR Shareholding & Total Voting Rights
2nd Nov 20164:35 pmRNSPrice Monitoring Extension
31st Oct 20167:00 amRNSPlacing and Subscription to raise £3.3 million
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
4th Oct 20164:35 pmRNSPrice Monitoring Extension
3rd Oct 20167:00 amRNSBlock Admission return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.